After holding various positions in the R&D department of LFB, Christine Guillen joined Transgene in October 2007 as Head of External Collaborations. In 2010, in parallel with her activities, she took over the management of antibodies projects, a role she had previously held in the company OPI (before its acquisition by Eusa Pharma) in which she held the position of Director of Project Management. During her career, Christine has conducted public-private collaborative R&D projects of amounting to more than 40 million euros.